Inicio>>Signaling Pathways>> Microbiology & Virology>> Parasite>>KDU691

KDU691

Catalog No.GC32118

KDU691, una imidazopirazina con potente actividad antiparasitaria contra esquizontes en estadio sanguÍneo, gametocitos y estadios hepÁticos, es un inhibidor de Plasmodium PI4K.

Products are for research use only. Not for human use. We do not sell to patients.

KDU691 Chemical Structure

Cas No.: 1513879-19-0

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
129,00 $
Disponible
5mg
117,00 $
Disponible
10mg
198,00 $
Disponible
25mg
436,00 $
Disponible
50mg
756,00 $
Disponible
100mg
1.339,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

KDU691 is a PI4K inhibitor.

During the 5 days of dosing, no major weight changes are observed in the animals that receive KDU691 as prophylactic treatment (group 691-proph). From the fourth day of dosing, the animals that are treated with KDU691 show a transient yellow skin color. The KDU691 radical-cure group (group 691-RC) becomes blood-stage positive again at 31.8±0.5 days p.i. (range, 31 to 32 days). Clinical chemistry analysis of the group 691-RC monkeys reveals that bilirubin levels accumulate during the 5-day radical-cure treatment with KDU691[1].

[1]. Zeeman AM, et al. PI4 Kinase Is a Prophylactic but Not Radical Curative Target in Plasmodium vivax-Type Malaria Parasites. Antimicrob Agents Chemother. 2016 Apr 22;60(5):2858-63.

Reseñas

Review for KDU691

Average Rating: 5 ★★★★★ (Based on Reviews and 33 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for KDU691

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.